BioRender 아이콘

LRP-2 (Megalin)

LRP-2 (Megalin) - Editable icon of a megalin or LRP2 receptor with complement-type repeats, EGF-type repeats, YWTD repeats, a transmembrane domain and NPXY motif
[{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5c8/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5c8/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5c7/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5c7/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5c6/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5c6/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5c5/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5c5/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5c4/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5c4/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5c3/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5c3/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5c2/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5c2/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5c1/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5c1/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5c0/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5c0/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5bf/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5bf/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5be/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5be/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5bd/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5bd/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5bc/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5bc/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5bb/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5bb/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5ba/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5ba/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5b9/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5b9/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5b8/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5b8/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5b7/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5b7/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5b6/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5b6/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5b5/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5b5/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5b4/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5b4/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5b3/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5b3/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5b2/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5b2/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5b1/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5b1/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5b0/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5b0/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5af/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5af/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5ae/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5ae/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5ad/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5ad/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5ac/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5ac/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5ab/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5ab/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5aa/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5aa/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5a9/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5a9/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5a8/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5a8/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5a7/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5a7/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5a6/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5a6/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5a5/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5a5/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5a4/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5a4/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5a3/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5a3/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5a2/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5a2/5fbd693303051c0027d1f527.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5fbd6f5503051c0027d1f5a1/5fbd693303051c0027d1f527.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5fbd6f5503051c0027d1f5a1/5fbd693303051c0027d1f527.png"}]
이 아이콘 사용하기 – 무료
가입 시 신용카드가 필요하지 않습니다.

이 아이콘은 BioRender에서 자유롭게 편집할 수 있습니다

  • 텍스트, 도형 및 기타 아이콘 추가
  • 5만 개 이상의 과학적으로 정확한 아이콘을 검색하세요
  • 모든 아이콘, 선, 라벨의 색상과 배치를 자유롭게 변경하세요
  • 어떤 용도로든 내보내거나 공유하세요
Scientist Avatars

이미 출판용 수준의 그림을 만들고 있는 400만 명 이상의 과학자들과 함께하세요

아이콘으로 몇 분 만에 완성된 그림을 만들어 보세요

  • 검색 50,000개 이상의 과학적으로 정확하고 동료 검토를 거친 아이콘 제공
  • 맞춤 설정 라벨, 도형, 추가 아이콘을 사용하여 모든 요소를 자유롭게 편집할 수 있습니다.
  • 내보내기 또는 공동 작업자와 그림 공유하기
    ‍

찾으시는 아이콘이 아닌가요? 더 많은 아이콘을 확인해 보세요.

30개 이상의 생명과학 분야에 걸친 50,000개 이상의 아이콘을 검색하세요.

search icon
arrow-right
megalin,LRP2,low density lipoprotein-related protein 2,EGF type,complement type,YWTD,NPXY,gp330,plasma membrane,endocytosis,endothelial,cubilin,thyroid,LRP2,megalin
더 보기

동의어를 검색하거나 가입하여 앱에서 아이콘을 요청해 보세요.

이미지 유형

LRP-2 (Megalin) icon JPEG

LRP-2 (Megalin) icon PNG

LRP-2 (Megalin) icon SVG

LRP-2 (Megalin) icon GIF

BioRender 아이콘 FAQ

How are scientists using the LRP-2 (Megalin) icon in their work?

BioRender users often use the LRP-2 (Megalin) icon in posters, grant applications, educational materials, and graphical abstracts. It’s especially useful for projects involving Proteins.

이 아이콘을 BioRender 그림이나 과학 일러스트레이션에 사용할 수 있나요?

Yes, the LRP-2 (Megalin) is fully integrated into BioRender’s drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you’re building from scratch or starting with a BioRender template.

Is the LRP-2 (Megalin) icon customizable in BioRender?

Most icons in BioRender, including the LRP-2 (Megalin) icon, are customizable. You can adjust icon size, colors, and positioning, and add custom labels to tailor the design to your specific research context.

Can I export figures that include the LRP-2 (Megalin) icon for publication or presentations?

Yes, figures containing the LRP-2 (Megalin) icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

How do I cite BioRender if I use this icon?

Unlock publication permissions with a paid plan, and include 'Created with BioRender.com' in your figure legend, or cite BioRender directly per your journal's guidelines.

Is the LRP-2 (Megalin) icon used in BioRender templates or poster layouts?

Many BioRender templates include icons like the LRP-2 (Megalin) icon — especially those focused on Proteins. You can search BioRender’s template library or add this icon manually to any canvas.

BioRender란 무엇인가요?

BioRender is a web‑based software that helps you create scientific figures in minutes. Use this LRP-2 (Megalin) icon along with our library of more than 30,000 life science icons.

BioRender에서 이 아이콘 사용하기

지금 바로 전문가 수준의 과학 피규어를 만들어 보세요
antibody elements3D Phospholipid illustration

과학 콘텐츠를 찾고 계신가요?

동료 검토를 거쳐 사용하기 쉽고 무료로 제공되는 5만 개 이상의 아이콘과 템플릿을 살펴보세요.

지금 바로 찾아보세요
x icon